FDA Drug · D-0649-2020

Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.

Class II · Terminated

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Affected lots / codes — check yours against thisBatch # 1905225VN, exp. date Apr-2021 1905226VD, exp. date Apr-2021 1906295UN, exp. date May-2021 1906296UN, exp. date May-2021 1906297UN, exp. date May-2021 1906298UD, exp. date May-2021

Recalling firm: Appco Pharma LLC, Piscataway, NJ
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 624 bottes
Distribution: Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.
Recall initiated: January 7, 2020
Classified: January 7, 2020
Terminated: April 24, 2020
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0649-2020%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →